Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-324-3 | CAS number: 27206-35-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute Toxicity Oral: Acute study oral (gavage), rat (Sprague-Dawley) m/f (OECD guideline 401, GLP): LD50(oral) > 2000 mg/kg / LD0(oral) ≥ 2000 mg/kg
Acute Toxicity Oral: Acute study oral (gavage), rat (Wistar) m/f (OECD guideline 401, GLP), read-across from 1-Propanesulfonic acid, 3-mercapto-, monosodium salt: LD50(oral) = 3720 mg/kg / LD0(oral) ≥ 2500 mg/kg
Acute Toxicity Dermal: Acute study dermal (occlusive), rat (Wistar) m/f (OECD guideline 402, GLP): LD50(dermal) > 2000 mg/kg / LD0(dermal) ≥ 2000 mg/kg
Acute Toxicity Dermal: Acute study dermal (occlusive), rat (Wistar) m/f (OECD guideline 402, GLP), read-across from 1-Propanesulfonic acid, 3-mercapto-, monosodium salt: LD50(dermal) > 7500 mg/kg / LD0(dermal) ≥ 7500 mg/kg
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 9 June - 2 July 1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (The Department of Health of the Government of the United Kingdom)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd. , Margate , Kent , UK
- Age at study initiation: 8 - 12 weeks
- Weight at study initiation: 212-229g (males) and 201-232g (females)
- Fasting period before study: overnight , until 3-4 hours after dosing
- Housing: animals were housed in groups of up to five by sex in solid-florr polypropylene cages furnished with woodflakes
- Diet : Rat and Mouse Expanded Diet No.1 (Special Diets Services Limited , Witham , Essex , UK) , ad libitum
- Water : mains drinking water , ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-22
- Humidity (%): 48-55
- Air changes (per hr): approximately 15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- other: distilled water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/ml
- Amount of vehicle (if gavage): 10 ml/kg bw - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The animals were observed for deaths or overt signs of toxicity 1/2 , 1 , 2 and 4 hours after dosing and subsequently once daily for fourteen days . Individual bodyweights were recorded prior to dosing on Day 0 and on Day 7 and 14 .
- Necropsy of survivors performed: yes , the animals were sublected to gross pathological examination
- Other examinations performed: behavioural and clinical observations , gross lesions , bodyweight changes , mortality , other toxicological effects - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occured during the study period
- Clinical signs:
- other: No signs of systemic toxicity were noted during the study
- Gross pathology:
- No abnormalities were noted at necropsy
- Interpretation of results:
- other: EU GHS criteria not met
- Conclusions:
- The study was performed according to the OECD TG401 without deviations and therefore considered to be of the highest quality (reliability Klimisch 1). The validity criteria of the test system are fulfilled. The test material did not induce mortality or treatment-related clinical signs. The test material was considered to be non-toxic under the conditions of the test.
- Executive summary:
A study was performed to assess the acute oral toxicity of the test material in the Sprague-Dawley CD strain rat. The method followed that in the OECD Guidelines for Testing of Chemicals No. 401 "Acute Oral Toxicity" (adopted 24 February 1987) and Method B1 of Commission Directive 92/69/EEC (which constitutes Annex V of Council Directive 67/548/EEC). Following a range-finding study, a group of ten fasted animals (five males and five females) was given a single oral dose of test material as a solution in distilled water at a dose level of 2000 mg/kg bodyweight. The animals were observed for fourteen days after the day of dosing and were then killed and subjected to gross pathological examination. There were no deaths. No signs of systemic toxicity were noted during the study. All animals showed an expected gain in bodyweight during the study. No abnormalities were noted at necropsy. The acute oral median lethal dose (LD50) of the test material in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/kg bodyweight. No symbol and risk phrase are required according to EU labelling regulations.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- There are two studies to cover that endpoint available: One assessed with Klimisch 1 on SPS itself, and one assessed with Klimisch 2 on the read-across substance MPS. They both gave consistent results, i.e. the LD50(oral) is > 2000 mg/kg, the LD0(oral) ≥ 2000 mg/kg. Hence, the tonnage-driven data requirements under REACH are fully met and the database is of high quality.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Waiver provides scientific explanation, taking into account reliable information on SPS derived from i.a. a Klimisch 1 studies, why the study does not need to be conducted. So the overall data quality justifying data waiving is high.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2015-05-26 - 2015-08-03
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Well-documented GLP OECD guideline study without relevant deviations on the registered substance itself
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- The relative air humidity exceeded 70% a few times. These changes were temporary and did not influence the study course and results.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- yes
- Remarks:
- The relative air humidity exceeded 70% a few times. These changes were temporary and did not influence the study course and results.
- Qualifier:
- according to guideline
- Guideline:
- other: Standard Operating Procedure SOP/T/21: „Acute dermal toxicity study”
- Deviations:
- yes
- Remarks:
- The relative air humidity exceeded 70% a few times. These changes were temporary and did not influence the study course and results.
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Wistar male and female rats (Cmdb: WI; outbred) coming from the husbandry of laboratory animals of the Experimental Medicine Centre at the Medical University in Białystok
- Age at study initiation: 8 weeks (males), 11 weeks (females)
- Weight at study initiation: average 267.8g (males) resp. 217.6g (females)
- Fasting period before study: no
- Housing: After the application of the test item, each animal was housed individually. After the removal of the test item from the animals’ skin, there were five rats in one cage. Each sex was kept separately.
- Diet (e.g. ad libitum): “Murigran” standard granulated fodder (batch number: 3/15, 4/15, 5/15) produced by Wytwórnia Koncentratów i Mieszanek Paszowych AGROPOL, Motycz, ad libitum
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 – 24 °C
- Humidity (%): 35 – 75%
- Air changes (per hr): about 16 times/hour
- Photoperiod (hrs dark / hrs light): 12 hours light/12 hours dark - Type of coverage:
- occlusive
- Vehicle:
- water
- Details on dermal exposure:
- TEST SITE
- Area of exposure: dorsal area of the trunk
- % coverage: 10% of the body surface area
- Type of wrap if used: gauze patch, PCV foil, elastic bandage and a sticking plaster
REMOVAL OF TEST SUBSTANCE
- Washing (if done): yes, with water
- Time after start of exposure: 24h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg b.w.
- Concentration (if solution): substance was moistened with a few drops of wwater
- For solids, paste formed: yes - Duration of exposure:
- 24h
- Doses:
- 2000 mg/kg b.w.
- No. of animals per sex per dose:
- 5/sex/dose
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: general conditions twice a day or once a day (on days off), clinical observations once a day, body weight on day 0, 7, 14
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, other: clinical observations, detailed gross examination which comprised the observation of the external body surface, all natural apertures, and the cranial, thoracic, and abdominal cavities with thei r contents - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: All animals survived the 14 day observation period.
- Sex:
- male/female
- Dose descriptor:
- LD0
- Effect level:
- >= 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: All animals survived the 14 day observation period.
- Mortality:
- All animals survived the experiment.
- Clinical signs:
- other: Following single application of the test item, the animals did not exhibit any general clinical signs. No pathological changes on the treated skin were noticed.
- Gross pathology:
- The gross examination did not reveal any pathological changes in the examined animals.
- Interpretation of results:
- other: EU GHS criteria not met
- Conclusions:
- The study was conducted under GLP according to OECD guideline 402 on the registered substance itself. The method is to be considered scientifically reasonable with no deficiencies in documentation. Hence, the results can be considered as reliable to assess the acute oral toxicity in rats.
Following single application of SPS at a dose of 2000 mg/kg bw, the animals did not show any general clinical signs. No pathological changes on the treated skin of males and females were found. All animals survived the experiment. During the 14-day experiment, body weight gain was found in all animals. Gross examination did not reveal any pathological changes in the examined animals. So it may be stated that the median lethal dose (LD50) of SPS is greater than 2000 mg/kg b.w. Since no animal showed at no observation time any pathological changes on the treated skin or other signs of irritation, it may be concluded that, under the conditions of this test, SPS does not need to be considered as irritating to rat skin.
According to the Regulation (EC) No. 1272/2008, it may be concluded that SPS is beyond categorization. - Executive summary:
In an acute dermal toxicity study (OECD 402), groups of 8-11 weeks old Wistar (Crl: WI(Han); outbred) rats (5/sex) were dermally exposed to moistened disodium 3,3'-dithiobis[propanesulphonate])(SPS) for 24 hours on 10% of body surface area at a dose of 2000 mg/kg bw under occlusive coverage. Animals then were observed for 14 days.
Following single application of the test item, the animals did not show any general clinical signs. No pathological changes on the treated skin of males and females were found. All animals survived the experiment. During the 14-day experiment, body weight gain was found in all animals. Gross examination did not reveal any pathological changes in the examined animals. Hence, the following results could be gained:
LD0(dermal) ≥ 2000 mg/kg bw
LD50(dermal) > 2000 mg/kg bw
SPS is of low Toxicity based on the LD50 determined. Since no animal showed at no observation time any pathological changes on the treated skin or other signs of irritation, it may be concluded that, under the conditions of this test, SPS does not need to be considered as irritating to rat skin.
According to Regulation (EC) No. 1272/2008, it may be concluded that SPS is beyond categorization.
Reference
Table 1 -Clinical signs-overall list
Dose (mg/kgb.w.) |
Sex |
Day after application |
Number of living animals |
Rat number |
||||
1 |
2 |
3 |
4 |
5 |
||||
|
|
0 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
1 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
2 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
3 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
4 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
5 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
6 |
5 |
NC |
NC |
NC |
NC |
NC |
|
males |
7 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
8 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
9 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
10 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
11 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
12 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
13 |
5 |
NC |
NC |
NC |
NC |
NC |
2000 |
|
14 |
5 |
NC |
NC |
NC |
NC |
NC |
|
0 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
|
1 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
2 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
3 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
4 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
5 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
6 |
5 |
NC |
NC |
NC |
NC |
NC |
|
females |
7 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
8 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
9 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
10 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
11 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
12 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
13 |
5 |
NC |
NC |
NC |
NC |
NC |
|
|
14 |
5 |
NC |
NC |
NC |
NC |
NC |
NC =no changes
Table 2 - Body weights of the animals (g) - overall list.
Dose (mg/kgb.w.) |
Sex |
Rat number |
Day of experiment / Body weight(g) |
Body weight gain(g) (0-14) |
||
0 |
7 |
14 |
||||
|
|
1 |
284 |
293 |
330 |
46 |
|
|
2 |
247 |
269 |
282 |
35 |
|
males |
3 |
254 |
267 |
284 |
30 |
|
|
|||||
|
|
4 |
270 |
271 |
292 |
22 |
2000 |
|
5 |
284 |
310 |
339 |
55 |
|
|
1 |
216 |
225 |
243 |
27 |
|
|
2 |
208 |
220 |
230 |
22 |
|
females |
3 |
211 |
221 |
232 |
21 |
|
||||||
|
|
4 |
225 |
226 |
242 |
17 |
|
|
5 |
228 |
227 |
233 |
5 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- There are two studies to cover that endpoint available: One assessed with Klimisch 1 on SPS itself, and one assessed with Klimisch 2 on the read-across substance MPS. They both gave consistent results, i.e. the LD50(dermal) is > 2000 mg/kg, the LD0(dermal) ≥ 2000 mg/kg. Hence, the tonnage-driven data requirements under REACH are fully met and the database is of high quality.
Additional information
In all available studies consistently no indication is given that the substance would need to be classified as acute toxic or poses any relevant risk for humans, as the animal model is considered sufficient to assess the inherent hazard of the substance via the oral or dermal route. Testing for toxicity via inhalation was considered not necessary as it would reveal no additional information and is also scientifically not relevant due to the intrinsic properties of SPS, e.g. low vapour pressure. The tonnage-driven data requirements are hence fully met, no data gaps were identified, and SPS does not need to be classified as acute toxic.
Justification for selection of
acute toxicity – oral endpoint
Most reliable study (Klimisch 1) via oral route on the registered
substance itself. Selection would not have any influence on the fact
that the substance does not require classification as both available
studies indicate that no animal dies at the limit dose of 2000 mg/kg.
Justification for selection of acute toxicity – inhalation endpoint
Provides explanation why study does not need to be conducted.
Justification for selection of acute toxicity – dermal endpoint
Most reliable study (Klimisch 1) via dermal route on the registered
substance itself. Selection would not have any influence on the fact
that the substance does not require classification as both available
studies showed that no animal died at the limit dose of 2000 mg/kg.
Justification for classification or non-classification
All available studies via the dermal or oral route revealed consistently LD50 and even LD0 (≥) values above 2000 mg/kg, which is the limit value for classification. Also, the given physico-chemical and toxicological data give no indication that testing for acute inhalation toxicity would result in LC50 values below 5 mg/L. Hence, classification criteria are not met and SPS does not need to be classified as acute toxic according to Regulation 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.